Table 1. Association of PA1 protein expression (Nuclear and Cytoplasmic) with clinicopathological parameters.

		PA1
	Total	Nuclear		Cytoplasm
Characteristic	(n = 344)	median (25%, 75%)	P value	median (25%, 75%)	P value
Age, y
≤50	99	95 (56, 125)	NS	0 (0, 90)	NS
>50	245	100 (45, 122)		0 (0, 96)
Menopausal state
Pre-	95	91 (44,124)	0.0097*	0 (0,80)	0.016*
Post-	247	100 (70, 156)		20 (0,98)
Tumor size
≤ 2cm	188	105 (71, 159)	0.0025*	30 (0, 97)	NS
> 2 cm	155	95 (45, 126)		0 (0, 90)
Axillary lymph nodes
Negative	217	100 (70, 146)	NS	10 (0, 97)	NS
Positive	113	95 (40, 143)		30 (0, 93)
Histopathology
Ductal	302	100 (60, 145)	NS	10 (0, 95)	NS
Lobular	10	82 (9, 162)		20 (0, 99)
Nuclear Grade
1,2	266	100 (60, 148)	NS	20 (0, 98)	NS
3	74	98 (58, 135)		0 (0, 90)
ERα
Negative	62	97 (49, 135)	NS	0 (0, 81)	0.0038*
Positive	282	100 (60, 148)		30 (0, 96)
PgR
Negative	101	98 (55, 146)	NS	0 (0, 90)	NS
Positive	241	100 (60, 145)		0 (0, 98)
HER2
Negative	298	100 (60, 146)	NS	10 (0, 95)	NS
Positive	46	93 (30, 111)		10 (0, 91)
Ki67 (MIB1 )
<15 %	121	111 (60, 160)	0.02*	15 (0, 91)	NS
≥15 %	206	98 (60, 130)		10 (0, 95)
AR
Negative	45	98 (13, 135)	0.049*	0 (0, 90)	NS
Positive	293	100 (70, 148)		20 (0, 95)
ERβ
Negative	77	90 (14, 118)	0.0020*	0 (0, 90)	0.051
Positive	218	102 (84, 150)		40 (0, 98)
Subtype
HR+ a/HER2-	264	100 (63, 148)	NS $	22.5 (0, 95)	NS $
HER2+	46	93 (30, 111)		10 (0, 91)
HR-/ HER2-	34	98 (60, 136)		0 (0, 83)

Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AR, androgen receptor, NS, not significant

^a HR(+): estrogen receptor (+) and/or progesterone receptor (+)

* Factor showing statistical significance.

^$ Kruskal-Wallis test